몬테루카스트 나트륨

동물 종별 용량

용량은 면허 수의 전문가를 위한 임상 참고 자료입니다. 항상 최신 라벨과 개별 환자에 대해 확인하십시오.

투여 경로

금기

• Hypersensitivity to montelukast or any component of the product
• Not for use in reversing acute bronchospasm (asthma attacks)

이상반응

• No significant adverse effects reported in cats to date
• Humans (rare): behavioral effects (aggression, suicidal thoughts), palpitations, cholestatic hepatitis, allergic granulomatous angiitis

약물 상호작용

• Phenobarbital · CYP-450 enzyme inducer; may reduce montelukast plasma concentrations and efficacy.
• Rifampin · CYP-450 enzyme inducer; may reduce montelukast plasma concentrations and efficacy.
• Prednisone / Prednisolone · Severe peripheral edema has been reported in a human receiving both drugs, presumably due to increased renal tubular sodium and fluid retention. Clinical significance in veterinary patients is unclear.

모니터링

• Clinical efficacy (improvement in respiratory or GI signs)

과용량

**Overdose Toxicity:** Montelukast is relatively safe in overdose situations. * **Animal Data:** Rats and mice survived oral doses of approximately 230X to 335X the usual human adult dose. * **Human Data:** Doses as high as 1,000 mg have been reported with the majority having no adverse effects. * **Clinical Signs (if present):** Headache, vomiting, psychomotor hyperactivity, thirst, somnolence, mydriasis, hyperkinesia, and abdominal pain. * **Treatment:** Basically supportive. No specific antidote is known.